Zoledronic acid (ZOL) significantly increases progression-free survival (FPS) versus clodronate and may improve response rates in newly diagnosed multiple myeloma (MM): MRC myeloma IX trail results

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Morgan G, Davies F, Gregory W, Cocks K, Bell S, Szubert A, Coy N, Drayson M, Feyler A, Ashcroft A, Owen R, Jackson G, Child J

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Haematologica: 15th Annual Meeting of the European Hematology Association

Year of Conference: 2010

Pages: 232

ISSN: 0390-6078

Publisher: Fondazione Ferrata Storti

Library holdings: Search Newcastle University Library for this item

ISBN: 15928721

ePrints